Efficacy and safety of recombinant human growth hormone therapy in pediatric intestinal transplant recipients

• Published in: Pediatric transplantation 2022-09, Vol.26 (6), p.e14321-n/a
• Main Authors: Vo, Hanh D., Elrokhsi, Salaheddin H., Iverson, Angela K., Keck, Megan A.
• Format: Article
• Language: English
• Subjects: Children; Endocrine therapy; growth hormone; Growth hormones; Growth rate; growth retardation; Intestine; Patients; Pediatrics; small bowel transplant; Small intestine; Velocity
• ISSN: 1397-3142; 1399-3046
• DOI: 10.1111/petr.14321

Background Recombinant human growth hormone (rhGH) is widely used to treat growth retardation in children. We aimed to examine the effect of rhGH therapy on growth and its impact on allograft function in children with growth retardation after intestinal transplant (IT). Methods We retrospectively included children younger than 19 years who had received an IT with or without the liver, were diagnosed with growth retardation, and have received rhGH between January 2010 and January 2021. Changes in the patient's anthropometric parameters between baseline and various time points were compared using the paired t‐test or Wilcoxon signed‐rank test, as appropriate. Results Seven patients (all males and prepubertal) received rhGH for the median duration of 2.3 years. The median age at rhGH start was 9.5 years. The median growth velocity z‐score improved from −0.95 before treatment to 2.3 (p = .04) and 1.9 (p = .06) after 1 and 2 years of treatment, respectively. The median height‐for‐age z‐score significantly improved from −3.4 at rhGH start to −1.3 (p = .005) at rhGH stop and remained above baseline at the last visit (−2.4, p = .002). The change in the first‐year growth velocity was negatively correlated with the change in the second‐year growth velocity (r = −.90, p = .04). No serious adverse effects or worsening allograft function were observed. Conclusions Severely growth retarded children after IT could benefit from rhGH treatment. A larger, longitudinal study would be warranted to monitor the long‐term effect and safety of rhGH and examine predictors of growth response to rhGH therapy in these pediatric IT recipients.